Oramed Pharmaceuticals Inc.

Day range

$4.04 – $4.20

Open

$4.14

Prev close

$4.13

Volume

61.29K

Market cap

$171.8M

Shares out

41.6M

P/E

0.99

P/S

—

P/B

0.54

P/FCF

—

ROE

54.8%

ROA

47.1%

Debt/Equity

0.00

Div yield

6.08%

As of Oct 23, 2026

• Annual meeting resultsSep 17, 2026

  The stockholders approved, on a non-advisory basis, the compensation of our named executive officers ("say-on-pay vote").

• Bylaw amendmentJun 30, 2026

  On June 28, 2026, the board of directors (the "Board") of Oramed Pharmaceuticals Inc. (the "Company") approved the Fifth Amended and Restated Bylaws (the "Amended Bylaws") of the Company, effective as of June 25, 2026. The Fifth Amended and Restated Bylaws amend and restate those certain Fourth Amended and Restated Bylaws of the Company, to (i) revise the record date procedures for stockholder action by written consent by providing that, if the Board of does not fix a record date within the applicable period, the record date will be fixed in accordance with Section 213(b) of the Delaware General Corporation Law, (ii) eliminate former Article III, Section 11(b), which required a stockholder requesting a record date for action by written consent to provide, among other information, certain information regarding the proposed action, related proposals and solicitation plans, and (iii) revise the effectiveness provision for stockholder consents to provide that consents signed by a sufficient number of stockholders must be delivered to the Company in accordance with applicable law within 60 days of the first date on which a consent is delivered to the Company.

• Warrant or conversionFeb 20, 2026

  the Company deferred its right to receive an amortization payment scheduled to be paid by Scilex on October 1, 2025 in exchange for Scilex's agreement to issue to the Company a new warrant to purchase an aggregate of 100,000 shares of Scilex's common stock, par value $0.0001 per share at an initial exercise price of $20.00 per share

• Debt issuanceJan 14, 2026

  The Company has agreed to purchase additional Notes (the "Additional Notes" and, together with the Initial Notes, the "Notes"), which are subject to the same terms as the Initial Notes, in an aggregate principal amount of $9,000,000 and accompanying warrants to purchase Ordinary Shares. The Notes mature on the three year anniversary of the respective date of issuance and bear an interest rate of 8% per annum payable semi-annually in arrears on June 30 and December 31 of each year commencing on December 31, 2026.

• Dividend declarationJan 7, 2026

  The Company's Board of Directors has approved a cash dividend payment of $0.25 per share to reward stockholders. The dividend will result in an aggregate distribution of approximately $10.5 million based on the current number of shares outstanding. The dividend will be paid on January 26, 2026, to stockholders of record as of January 16, 2026.

Days to cover

7.3

Short interest

1.43M

Avg volume

195.6K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
  positiveBenzinga· Jun 17, 2026
• Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
  positiveGlobeNewswire Inc.· Mar 13, 2026
• Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
  positiveBenzinga· Jan 7, 2026
• ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
  neutralBenzinga· Nov 17, 2025
• Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
  positiveBenzinga· Feb 11, 2025